Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the transaction, the insider directly owned 51,871 shares in the company, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Alexander Smith also recently made the following trade(s):

• On Tuesday, February 3rd, Michael Alexander Smith sold 640 shares of Insmed stock. The shares were sold at an average price of $156.27, for a total value of $100,012.80.
• On Thursday, January 8th, Michael Alexander Smith sold 1,053 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $183,401.01.
• On Wednesday, January 7th, Michael Alexander Smith sold 709 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $124,124.63.
• On Tuesday, January 6th, Michael Alexander Smith sold 1,396 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $241,968.68.

Insmed Stock Down 1.0%

NASDAQ:INSM traded down $1.68 during mid-day trading on Thursday, reaching $163.18. The company’s stock had a trading volume of 221,322 shares, compared to its average volume of 2,527,628. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The stock has a fifty day moving average of $150.14 and a 200-day moving average of $166.41. The firm has a market capitalization of $35.17 billion, a PE ratio of -25.45 and a beta of 1.10.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same period last year, the business posted ($1.32) EPS. The company’s revenue for the quarter was up 152.6% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Hedge Funds Weigh In On Insmed

A number of large investors have recently made changes to their positions in INSM. Choreo LLC purchased a new position in Insmed during the 2nd quarter worth $227,000. Edgestream Partners L.P. purchased a new stake in Insmed in the second quarter valued at about $429,000. Quantbot Technologies LP acquired a new stake in Insmed in the second quarter worth about $2,221,000. CW Advisors LLC purchased a new stake in shares of Insmed during the second quarter worth about $576,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Insmed by 65.6% during the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 263 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on INSM shares. Roth Mkm upgraded Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Wolfe Research set a $167.00 price target on Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Mizuho lifted their target price on Insmed from $204.00 to $206.00 and gave the company an “outperform” rating in a research note on Wednesday, March 25th. Finally, Stifel Nicolaus boosted their target price on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Insmed currently has an average rating of “Buy” and a consensus target price of $212.67.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.